Saenz R E, de Rodriguez C G, Johnson C M, Berman J D
Gorgas Memorial Laboratory, Panama City, Panama.
Am J Trop Med Hyg. 1991 Apr;44(4):394-8. doi: 10.4269/ajtmh.1991.44.394.
We tested the World Health Organization (WHO) recommended treatment for mucosal leishmaniasis in 16 Panamanians with disease due to Leishmania braziliensis panamensis. Disease was mild in this population because it was limited to the nasal mucosa and only one patient had septal perforation. The patients were administered 20 mg antimony (in the form of Pentostam) per kg intravenously each day for 28 days. Ten patients completed therapy and were cured at 12 month follow-up. Three patients completed therapy, healed their lesions, but relapsed at the six or 12 month follow-up. Three patients terminated therapy prematurely because of liver enzyme elevations in conjunction with either EKG abnormalities or musculoskeletal complaints; none of these patients were healed. This study indicates that in patients with mild mucosal leishmaniasis, the WHO regimen is curative in 77% patients who complete treatment and in 63% of all patients.
我们对16名因巴拿马利什曼原虫感染而患黏膜利什曼病的巴拿马患者，采用了世界卫生组织（WHO）推荐的治疗方法。该人群的病情较轻，因为病变仅局限于鼻黏膜，只有一名患者出现鼻中隔穿孔。患者每天静脉注射20毫克锑（以喷他脒形式），每千克体重用药，持续28天。10名患者完成治疗，在12个月的随访中治愈。3名患者完成治疗，病变愈合，但在6个月或12个月的随访中复发。3名患者因肝酶升高并伴有心电图异常或肌肉骨骼不适而提前终止治疗；这些患者均未治愈。本研究表明，对于轻度黏膜利什曼病患者，WHO方案在完成治疗的患者中治愈率为77%，在所有患者中的治愈率为63%。
